NLS Pharmaceutics (NASDAQ:NCEL) Stock Price Up 7.5% – Still a Buy?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL)’s stock price was up 7.5% during trading on Tuesday. The stock traded as high as $2.80 and last traded at $2.74. Approximately 12,391 shares traded hands during trading, The stock had previously closed at $2.55.

Wall Street Analysts Forecast Growth

NCEL has been the subject of several research analyst reports. Weiss Ratings upgraded shares of NLS Pharmaceutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 18th. Laidlaw began coverage on NLS Pharmaceutics in a research report on Monday, July 13th. They set a “buy” rating and a $23.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $23.00.

NLS Pharmaceutics Price Performance

The business’s fifty day moving average price is $3.05 and its 200 day moving average price is $3.09.

NLS Pharmaceutics (NASDAQ:NCEL) last issued its quarterly earnings results on Friday, September 18th. The company reported ($0.48) earnings per share for the quarter.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research has centered on therapies intended to address significant unmet needs in narcolepsy and related disorders.

Its principal development program has been Quilibria, an extended-release formulation of mazindol designed to treat excessive daytime sleepiness associated with narcolepsy and potentially other hypersomnia disorders.